Patrys has struck a binding agreement with Yale that hands the university ownership of the deoxymab intellectual property while securing Patrys a 50 per cent share of any future commercialisation revenue directly attributable to the deoxymab portfolio.
Latest Video
New Stories
-
Canberra discovers what it really feels like to face a single buyer, and the response is hypocrisy
November 17, 2026 - - Latest News -
US biotech lobby's call for a White House strategy echoes AusBiotech push
November 17, 2026 - - Latest News -
Third global honour of 2026 for cochlear implant pioneer Graeme Clark
November 17, 2026 - -
Ipsen marks 25 years in Australia as rare disease listings broaden patient access
November 17, 2026 - - Latest News -
Can the PBS afford another agreement on the same terms?
November 16, 2026 - - Latest News -
First official US count confirms the broad uptake of GLP-1s for weight management
November 16, 2026 - - Latest News -
Medicines Australia tells productivity inquiry PBS rules leave out economic benefits
November 16, 2026 -

